methotrexate polyglutamates
Recently Published Documents


TOTAL DOCUMENTS

78
(FIVE YEARS 10)

H-INDEX

18
(FIVE YEARS 1)

2021 ◽  
Vol 14 (5) ◽  
pp. 463
Author(s):  
Ryan Morrow ◽  
Ryan Funk ◽  
Mara Becker ◽  
Ashley Sherman ◽  
Leon Van Haandel ◽  
...  

Inside cells, the immunomodulator methotrexate (MTX) undergoes the addition of glutamates to form methotrexate polyglutamates (MTX-Glu)—promising biomarkers of systemic exposure and treatment response to MTX in rheumatology. MTX-Glu are underexplored in Inflammatory Bowel Disease (IBD), with no data in pediatrics. In this cross-sectional secondary analysis, we assessed the relationships between MTX-Glu and MTX dose and treatment response in pediatric IBD. Twenty-one children with IBD, receiving maintenance therapy with infliximab (IFX) and MTX, had MTX-Glu1–6 concentrations and IFX troughs/antibodies measured and disease activity assessed for comparison in remission vs. active IBD using non-parametric tests, with associations explored using Spearman’s correlation (ρ) and regression analyses; SASv9.4 (α = 0.05). Total and long-chain MTX-Glu correlated with MTX dose (ρ = 0.51 and 0.56, respectively; p ≤ 0.02). In children with Crohn’s disease (n = 19), short-chain MTX-Glu1–2 were 2.5-fold higher in remission vs. active disease, approaching statistical significance (p = 0.066), with no statistical differences in IFX trough (p = 0.549) between groups. Our study highlights a potential role for long-chain MTX-Glu in the therapeutic drug monitoring of MTX in IBD. It is the first study in pediatric IBD and, although statistical significance was not reached, our findings also suggest that higher short-chain MTX-Glu levels may be associated with IBD treatment response to MTX in children.


2021 ◽  
Author(s):  
Yiming Zhang ◽  
Liyu Sun ◽  
Libo Zhao ◽  
Xiaoling Wang ◽  
Zhigang Zhao ◽  
...  

2020 ◽  
Vol 130 (12) ◽  
pp. 6600-6615
Author(s):  
Elixabet Lopez-Lopez ◽  
Robert J. Autry ◽  
Colton Smith ◽  
Wenjian Yang ◽  
Steven W. Paugh ◽  
...  

2020 ◽  
Vol 13 ◽  
pp. 10-13
Author(s):  
Mamatha Pasnoor ◽  
Andrew J. Heim ◽  
Laura Herbelin ◽  
Jeffrey Statland ◽  
Mazen M. Dimachkie ◽  
...  

Introduction. Methotrexate (MTX) is an immunosuppressive and anti-inflammatory drug used to treat rheumatoid arthritis (RA) and other autoimmune conditions. MTX is transported into cells, where glutamate moieties are added and is retained as methotrexate polyglutamates (MTXPGs). In the RA literature, it has been reported that the degree of polyglutamation correlates with the anti-inflammatory effect of MTX in RA. There are no prior studies evaluating the relationship between MTXPGs and myasthenia gravis (MG) outcome measures. The objective of this study was to assess the correlation between methotrexate (MTX) polyglutamates (MTXPGs) with Myasthenia Gravis (MG) outcome measures. Methods.xAn analysis was done of blood drawn from patients enrolled in the 12-month randomized, placebo-controlled study of MTX in MG study. Red blood cell MTXPGs were measured via ultraperformance liquid chromatography and tandem mass spectrometry. MTXPG was correlated to MG outcome measures using Spearman Correlation Coefficient. A two-group t-test was used to determine the difference in MTXPG based on clinical outcome responder definitions. Results. Twenty-one polyglutamate samples were analyzed of subjects on MTX while eight samples were analyzed from subjects on placebo. Pentaglutamate had the strongest correlation with the MG-ADL (0.99), while tetraglutamate had the strongest correlation with the QMG (0.54). Triglutamate had the strongest correlation with MGC (0.76). Conclusion. There were variable correlations between MTXPG1-5 and MG outcomes (rho range: 0.08 to 0.99). There are strong correlations between MTXPG and the MG-ADL, QMG, and MGC. Long chain methotrexate polyglutamates correlate better with MG outcomes.


Medicina ◽  
2019 ◽  
Vol 55 (12) ◽  
pp. 758
Author(s):  
Alma Mendoza-Santiago ◽  
Edgardo Becerra ◽  
Edith Garay ◽  
Moustapha Bah ◽  
Laura Berumen-Segura ◽  
...  

Background and Objectives: Acute lymphoblastic leukemia (ALL) is the most common type of cancer in childhood. The majority of patients respond to treatment, but those with resistant phenotypes suffer relapse or death. The antifolate methotrexate (MTX) is the most commonly used drug against ALL due to its efficacy. Once inside leukemic cells, MTX is metabolized into methotrexate polyglutamates (MTX-PG) by action of the enzyme folylpolyglutamate synthetase (FPGS), leading to a longer action compared to that of MTX alone. Materials and Methods: In this work, we demonstrated that the combination treatment of methotrexate and 5 and 10 mM glutamic acid could enhance methotrexate cytotoxicity in CCRF-SB (B-ALL) cells. In addition, MTX plus 20 mM glutamic acid was able to improve the synthesis of MTX-PG5. Results: All treatments induced an increase in FPGS expression compared to that of the control group. Furthermore, we detected different cellular expression patterns of FPGS in the different treatments. Conclusion: Based on these findings, we demonstrated that levels of methotrexate polyglutamates (MTX-PGs) could be a key determinant of methotrexate-induced cytotoxicity in CCRF-SB acute lymphoblastic leukemia cells.


2019 ◽  
Vol 25 (Supplement_1) ◽  
pp. S25-S25
Author(s):  
Valentina Shakhnovich ◽  
Taina Jausurawong ◽  
Ryan Morrow ◽  
Mara Becker ◽  
Ryan Funk

Sign in / Sign up

Export Citation Format

Share Document